82 results about "Beta-Adrenergic Agonist" patented technology

Combinations comprising (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.

The present invention relates to sodium channel blockers. The present Invention also includes a variety of methods of treatment using these inventive sodium channel blockers.

The present invention discloses a novel compound and method for the treatment of inflammatory autoimmune diseases, for example, rheumatoid arthritis, using α-adrenergic antagonists and β-adrenergic agonists in combination. Treatment of animals, namely humans, with an α-adrenergic antagonist, preferably, phentolamine, and a β-adrenergic agonist, preferably terbutaline, in combination can significantly suppress the joint destruction and inflammation due to disease in these animals.

The present invention provides sodium channel blockers possessing beta-adrenergic receptor agonist activity.

The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.

A method of delivery of a combination therapy to the pulmonary system that includes providing a nebulizer and an aqueous solution comprising a long-acting corticosteroid, a long-acting beta-agonist, and a long-acting anticholinergic, and administering the solution to the patient using the nebulizer. The corticosteroid is budesonide, the beta-agonist is formoterol and the anticholinergic is tiotropium. A pharmaceutical composition is also described for the treatment of respiratory conditions and diseases comprising a long-acting corticosteroid, a long-acting beta-agonist, and a long-acting anticholinergic, and administering the solution to the patient using the nebulizer.

The invention provides a liquid chromatography-mass spectrometry method for rapidly detecting the content of beta-agonists. The liquid chromatography-mass spectrometry method comprises the following steps: pretreating a sample, namely, sequentially adding water and an organic extracting solution in the sample for extracting a beta-receptor stimulant; then adding a salting-out agent and a water removing agent to ensure that the organic extracting solution and a water phase demix, centrifuging to obtain a first supernate, adding an adsorbing agent in the first supernate for purification, centrifuging to obtain a second supernate, concentrating, re-dissolving and filtering the second supernate to prepare a sample to be detected; and then detecting the beta-receptor stimulant contained in an animal-derived food by adopting an ultra-high performance liquid chromatography-triple quadrupole mass spectrometer. According to the sample pretreatment method suitable for liquid chromatography-mass spectrometry detection, provided by the invention, interfering molecules are removed through extraction and purification so that high accuracy is achieved in sample detection.

Provided are pressurized metered dose inhalers containing stable formulations of a beta-agonist drug in suspension or solution. Also provided are aerosol formulations suitable for inhalation therapy containing a beta-agonist drug in suspension or solution.

A method of delivery of a combination therapy to the pulmonary system that includes providing a nebulizer and a fluid comprising a long-acting corticosteroid, a long-acting beta-agonist, and a long-acting anticholinergic in a pharmaceutically acceptable vehicle, and administering the solution to the patient using the nebulizer. The corticosteroid is budesonide, the beta-agonist is formoterol and the anticholinergic is tiotropium in a an aqueous solution, suspension or emulsion suitable for administration with the nebulizer.

The present invention relates to new beta-agonists of general formula 1: wherein the groups R<1 >to R<12 >have the meanings given in the claims and specification, the isomers thereof, processes for preparing these compounds and their use as pharmaceutical compositions.

The present invention relates to multifunctional β-agonist compounds comprising a reactive oxygen species scavenger group and a nitric oxide donor, and their use for the treatment of respiratory diseases involving airway obstruction, such as asthma and chronic bronchitis. The invention further relates to methods and devices for administering the compounds.

New chemical entities which comprise corticosteroids and phosphorylated β-agonists for use in therapy and compositions comprising and processes for preparing the same.

The invention provides a method for extracting and analyzing beta-agonists clenbuterol by adopting a DPX (dispersive pipette extraction) tip type dispersive solid-phase microextraction column and relates to the DPX tip type dispersive solid-phase microextraction column (DPX tips <TM>). The method can be matched with various manual and automatic pipetting systems, meat sample treatment and extraction can be completed rapidly and efficiently, and defects that traditional sample treatment is time-consuming and labor-consuming, instrument loss is increased and the like can be perfectly overcome. The simple and fast solid-phase extraction method is combined with HPLC-MS (high performance liquid chromatography-mass spectrometer) analysis, so that purification of 96-384 samples can be finished simultaneously within 10 min, and rapid, qualitative and quantitative high-flux determination for multiple kinds of beta-agonists clenbuterol in animal derived food can be realized.

The invention discloses a halogen-substituted phenyl ether compound and an application thereof. Specifically provided are a compound represented by formula (I) or an optical isomer, a pharmaceuticallyacceptable salt, a prodrug, a hydrate or a non-aqueous solvate thereof. The experiments prove that compared with a control compound MGL-3196, the compound shown in the formula (I), which is obtainedthrough a specific substitution position and a specific substitution type, has better agonistic activity on THR-beta, and the selectivity on THR-beta/THR-alpha is remarkably improved. In addition, thecompound provided by the invention also has significantly improved pharmacokinetic properties. The compound provided by the invention has excellent application prospects in preparation of THR-beta agonists and medicines for treating indications (including dyslipidemia, hypercholesterolemia, non-alcoholic steatohepatitis and non-alcoholic fatty liver diseases) suitable for the THR-beta agonists.

The present invention relates to new beta-agonists of general formula (I)

wherein the groups R¹ to R⁴ have the meanings given in ths claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates, mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, methods of preparing these compounds and their use as pharmaceutical compositions.

Compositions, formulations, methods, and systems for treating thyroid eye disease and related conditions (e.g., Grave's Ophthalmopathy). The methods described herein include administering, to a patient in need, systemic or local beta adrenergic agonists (e.g., as an extended release crystalline microparticle suspension). The methods can further include administering a compound for reducing beta adrenergic receptor desensitization (e.g., a corticosteroid) prior to administering or coadministered with the beta adrenergic agonist. The methods can also include locally administering to the eye an immunosuppressant agent (e.g., rapamycin) prior to administering a beta adrenergic agonist. The compositions described herein include ophthalmic pharmaceutical formulations of beta adrenergic agonists in the form of extended release crystalline microparticle suspensions or mixtures of the crystalline microparticle suspensions with beta adrenergic agonist solutions. The compositions also include ophthalmic formulations of a compound for reducing beta adrenergic receptor desensitization in the form of extended release crystalline microparticle suspensions.

The invention relates to a multi-cluster antigen and an antibody of beta-adrenoceptor agonists and application of the multi-cluster antigen and the antibody to detection on multi-residue of the beta-adrenoceptor agonists. The application is implemented by a detection kit and test paper. The multi-cluster antigen of the beta-agonists is salbutamol-ractopamine-bovine serum albumin (SAL-RAC-BSA) or salbutamol-ractopamine-ovalbumin (SAL-RAC-OVA), and the salbutamol-ractopamine-bovine serum albumin antibody (SAL-RAC-BSAAb) is prepared from SAL-RAC-BSA through animal immunization. The invention also discloses the kit and the test paper, which are used for detecting the multi-residue of the beta-agonists and take the SAL-RAC-BSAAb as a core agent. Based on a cross immunization reaction of the SAL-RAC-BSAAb on the beta-agonists, three beta-agonists, namely clenbuterol, SAL and RAC, can be detected.

The present invention relates to powder formulations for inhalation containing enantiomerically compounds of general Formula (I) wherein the groups R¹, R² and R³ may have the meanings indicated in the claims and in the specification, optionally in the form of the pharmaceutically acceptable acid addition salts thereof, and optionally in combination with a pharmaceutically acceptable excipient, processes for preparing them and their use as medicaments, particularly as medicaments for the treatment of respiratory complaints.

A mutual prodrug of an AISTM and a β-agonist in formulation for delivery by aerosolization to inhibit pulmonary inflammation and bronchoconstriction is described. The mutual prodrug is preferably formulated in a small volume solution (10-500 μL) dissolved in a quarter normal saline having pH between about 5.0 and 7.0 for the treatment of respiratory tract inflammation and bronchoconstriction by an aerosol having mass median average diameter predominantly between about 1 to 5μ, produced by nebulization or by dry powder inhaler.

The present invention relates to new beta-agonists of general formula (I)

wherein the groups R¹ and R² have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates, mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, methods of preparing these compounds and their use as pharmaceutical compositions.

The invention relates to the field of biological detection and discloses a detection device and a detection method of a large class of beta-agonists drugs by applying an immune chromatography technology. According to the invention, an antibody/receptor which is reacted with a large class of the beta-agonists drugs is used for preparing an immune chromatography test strip to realize the simultaneous detection of a large class of the beta-agonists drugs. Compared with the prior art, the detection on a large class of the beta-agonists drugs for one time can be realized, the detection cost is low and the method is convenient and fast.